Maureen Newman is a researcher by trade, and brings her knowledge of the lab to BioNews Texas. Currently, she is serving as a PhD student at University of Rochester, and working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit’s laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment. She is a senior science and research columnist for BioNews Texas.
This week at the Scleroderma Foundation of Southern California’s 17th annual “Key to a Cure” gala, Genentech‘s Senior Group Medical Director of Immunology, Dr. Jeffrey Siegel, will receive the ... Read more
Top-line results from the Apricus Biosciences, Inc. Phase 2a clinical trial for RayVa™ topical treatment in patients with scleroderma-related Raynaud’s phenomenon indicate the treatment is safe and effective. Patients ... Read more
Preliminary results for the Phase 2 LARIAT clinical trial conducted by Reata Pharmaceuticals for bardoxolone methyl in pulmonary arterial hypertension will be presented at the upcoming 2015 American College ... Read more
Tiny pieces of damaged endothelial cells, aptly called “microparticles” due to their size, can be generated in patients with systemic sclerosis (SSc). These cell particulates are created from a variety ... Read more
A collaboration between Bristol-Myers Squibb Company and The Medical University of South Carolina (MUSC) will focus on translational research for developing scleroderma and other fibrotic disease treatments. The goal ... Read more
Patients in the LOTUSS study who were treated for systemic sclerosis-associated idiopathic pulmonary fibrosis (SSc-IPF) using Esbriet (pirfenidone) showed signs of drug tolerability, according to a presentation at the European ... Read more
It’s a breakthrough: Roche has been awarded breakthrough therapy designation status for its ACTEMRA®/RoACTEMRA® (tocilizumab) treatment in patients with systemic sclerosis. The designation will enable Roche to speed up ... Read more